These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21050861)

  • 1. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
    Braga CA; Follmer C; Palhano FL; Khattar E; Freitas MS; Romão L; Di Giovanni S; Lashuel HA; Silva JL; Foguel D
    J Mol Biol; 2011 Jan; 405(1):254-73. PubMed ID: 21050861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
    Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D
    Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
    Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
    J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
    Park SS; Lee D
    Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
    Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
    Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine.
    Jain MK; Bhat R
    Neurobiol Dis; 2014 Mar; 63():115-28. PubMed ID: 24269918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
    Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
    J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis.
    Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S
    Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
    Bharathi ; Indi SS; Rao KS
    Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
    Ono K; Hirohata M; Yamada M
    J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
    Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
    FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
    Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
    Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.